JNJ - Johnson & Johnson
| Previous Close | 121.45 |
| Open | 121.68 |
| Bid | 123.60 x 1000 |
| Ask | 123.80 x 1200 |
| Day's Range | 121.65 - 123.38 |
| 52 Week Range | 118.62 - 148.32 |
| Volume | 10,305,307 |
| Avg. Volume | 6,657,515 |
| Market Cap | 329.475B |
| Beta | 0.56 |
| PE Ratio (TTM) | 271.77 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | 3.60 (2.96%) |
| Ex-Dividend Date | 2018-05-25 |
| 1y Target Est | N/A |
- CNBC Videos•6 days ago
Cramer floats idea for 'gloomy' ETF with Wall Street's mo...
Jim Cramer proposes starting a new exchange-traded fund with the stocks that scare investors most when trade tensions run high.
- CNBC Videos•6 days ago
Cramer floats idea for 'gloomy' ETF
Jim Cramer proposes starting a new exchange-traded fund with the stocks that scare investors most when trade tensions run high.
- MarketWatch•yesterday
This one factor has determined which stocks rise or fall on trade-war fears
In a volatile year for the U.S. equity market, one factor has emerged as pivotal in determining whether a stock is likely to rise amid growing concerns over trade policy: how much the U.S. company focuses on the U.S.
- Bloomberg•2 days ago
J&J's Drug Unit Chief Expands Portfolio in Executive Shakeup
Johnson & Johnson’s head of pharmaceuticals, Joaquin Duato, will add the company’s consumer business to his portfolio in an executive shakeup at the U.S. health-care conglomerate. J&J said Friday that Duato, 56, will take over much of the portfolio overseen by Sandra Peterson, 59, who is retiring on Oct. 1. Duato and Paul Stoffels, who leads J&J’s drug research and development, will both be named vice chairmen of the New Brunswick, New Jersey-based company’s executive committee.
- The Wall Street Journal•2 days ago
[$$] Johnson & Johnson Remakes Top Leadership
, J&J’s No. 2 the past six years, plans to retire from her post on Oct. 1. Ms. Peterson, 59 years old, had led J&J’s efforts to turn around its consumer-health business struggling with recalls. More recently, she had been overseeing a rejiggering of J&J’s medical-device business.
Markit•2 days agoSee what the IHS Markit Score report has to say about Johnson & Johnson.
Johnson & Johnson NYSE:JNJ
- TheStreet.com•3 days ago
Crowning Achievement: Six Dividend Kings With 50+ Years of Rising Dividends
The "Dividend Kings" are the pinnacle of dividend stock royalty. A long dividend history is important because it proves that a company has been able to maintain its competitive advantage over the long run. This article has detailed analysis on our six favorite Dividend Kings.
Market Realist•3 days agoJohnson & Johnson Releases Positive Study Data for Oncology Drug
On June 3, Johnson & Johnson’s (JNJ) pharma subsidiary, Jannsen, released data from a Phase 2 study of erdafitinib for the treatment of patients with metastatic or unresectable urothelial carcinoma (or mUC). Johnson & Johnson presented the study results at the 2018 ASCO (American Society of Clinical Oncology) Annual Meeting, along with results for some of its other oncology drug trials, as shown in the diagram below. Jannsen’s erdafitinib, a once-daily oral pan-FGFR (fibroblast growth factor receptor) inhibitor, was designated a breakthrough therapy by the FDA in March.
- Market Realist•3 days ago
Johnson & Johnson Receives Offer to Divest Sterilization Business
On June 6, Johnson & Johnson (JNJ) announced it had received a $2.8 billion offer from Fortive (FTV) to sell its ASP (Advanced Sterilization Products) business, part of its subsidiary, Ethicon. Ethicon’s ASP business, a market leader in infection prevention solutions, generated sales of $775 million in fiscal 2017. Johnson & Johnson has 120 days to decide on the offer.
- Market Realist•3 days ago
Johnson & Johnson Accepts Sale of Its LifeScan Business
On June 12, Johnson & Johnson (JNJ) announced it had accepted a $2.1 billion offer for the sale of its LifeScan business, which manufactures blood glucose monitoring devices and OneTouch products, from private equity company Platinum Equity. On June 12, JNJ stock fell ~0.42% following the deal announcement.
- Market Realist•4 days ago
How Johnson & Johnson’s Valuation Compares
Johnson & Johnson (JNJ), one of the world’s largest healthcare companies, has a diversified business spanning its consumer, medical device, and pharmaceutical segments. The company reported sales of $20 billion in Q1 2018 and adjusted EPS of $2.06. Let’s look at Johnson & Johnson’s valuation metrics.
Market Realist•4 days agoA Look at Johnson & Johnson’s Stock Performance
Johnson & Johnson (JNJ) closed June 18 at $121.30 per share. The stock reached a 52-week low of $118.60 on May 29 as the company scrapped a Phase 1b/2 trial for its drug, Darzalex, for the treatment of advanced or metastatic non-small cell lung cancer patients, in combination with Roche’s (RHHBY) Tecentriq. Since then, the stock has risen ~1.6%.
- Market Realist•4 days ago
What Analysts Recommend for Johnson & Johnson Stock
Johnson & Johnson (JNJ) is one of the biggest healthcare players in the world. However, it has been impacted by growing competition and pricing pressure in the industry in recent years and has revised its strategy. The company has witnessed recuperating sales in its medical devices business along with improving dynamics in its consumer business, which has encountered some litigation recently. The company’s pharmaceuticals business has performed steadily, with key trial data being announced. Let’s look at analysts’ recommendations for JNJ stock.
- Market Realist•4 days ago
A Look at Allergan’s Valuation as of June 19
Allergan (AGN), a leading specialty pharmaceutical company, is focused on developing, manufacturing, and commercializing pharmaceutical and biologic products.
- Motley Fool•4 days ago
Forget Johnson & Johnson: Here Are 2 Better Dividend Stocks
J&J's dividend is good. But these are even better.
American City Business Journals•4 days agoHere’s how much Houston public companies spent on litigation in 2017
Meanwhile, the nation’s largest banks are preparing for a timeout from the courtroom following years of being pummeled by shareholder and investor lawsuits in the wake of the Great Recession.
Market Realist•5 days agoWhat’s the Latest on Teva’s Fremanezumab?
Teva’s (TEVA) much-awaited migraine drug, Fremanezumab, is in late-stage trials for the treatment of cluster headaches. The company provided an update regarding its Enforce Phase III clinical development program for the treatment of cluster headaches on June 15.
- TheStreet.com•5 days ago
The Charts and Indicators on Johnson & Johnson Are Still Mostly Bearish
is another company that Jim Cramer put in his new GLOOM index last night on his Mad Money show on CNBC. In this updated daily bar chart of JNJ, below, we have more bearish signals than bullish ones. JNJ broke down below the rising 50-day moving average line in late January and the slope of the line quickly turned negative.
- Bloomberg•5 days ago
Opioid Ruling Could Send Purdue, Drugmakers to Court
Purdue Pharma LP, Johnson & Johnson and other opioid makers faced one of the first extensive review of their legal defenses to state claims that they violated consumer-protection laws and created a public nuisance with the sale of the pain killers. New York state court Judge Jerry Garguilo on Monday rejected the pharma companies’ requests for the lawsuits be thrown out on a myriad of grounds, concluding lawyers for eight counties could move forward with their claims. While the ruling is based solely on New York law, it could provide a roadmap for other judges around the U.S. weighing whether states and local governments can proceed with claims that Purdue and other opioid makers understated the risks of prescription opioids and overstated their benefits.
- Motley Fool•5 days ago
3 Stocks That Are Absurdly Cheap Right Now
When stocks become nonsensically priced due to irrational market decisions, investors should act on the opportunity.
- Reuters•6 days ago
FOCUS-After split from Actelion, Idorsia CEO plans to raise more cash in 2019
Swiss biotech Idorsia, spun off from Actelion last June with a $1 billion investment from buyer Johnson & Johnson, will seek fresh funding in 2019 to support late-stage trials of drugs getting underway, its CEO told Reuters. French founders Jean-Paul Clozel and his wife, Martine Clozel, sold Actelion for $30 billion last year, but only after extracting rights to 11 prized drugs in development, including an insomnia medicine nicknamed DORA.
Associated Press•6 days agoMarkets Right Now: Stocks look to recover from early skid
NEW YORK (AP) — The latest on developments in financial markets (all times local):
- TheStreet.com•6 days ago
3 Great Stocks for Retirees to Own
Congratulations! You've just retired. Investors and financial planners both suggest that dividend stocks can be a great source of income for those looking to supplement their retirement savings. The blue-chip stock's staying power and brand recognition should be viewed favorably by retiree investors, says Robert Johnson, principal at the Fed Policy Investment Research Group.
- Reuters•6 days ago
After split from Actelion, Idorsia CEO plans to raise more cash in 2019
Swiss biotech Idorsia, spun off from Actelion last June with a $1 billion investment from buyer Johnson & Johnson, will seek fresh funding in 2019 to support late-stage trials of drugs getting underway, its CEO told Reuters. French founders Jean-Paul Clozel and his wife, Martine Clozel, sold Actelion for $30 billion last year, but only after extracting rights to 11 prized drugs in development, including an insomnia medicine nicknamed DORA. With 650 employees, Jean-Paul Clozel expects to burn through Idorsia's cash in about two years, before his drug hopefuls generate revenue - typical of the biotech industry where the risk of pipeline failures is ever-present but the rewards of striking paydirt, as was the case with Actelion, can be vast.
- Motley Fool•6 days ago
Why Geron Corporation Stock Is Heading Higher Today
The company's EHA conference over the weekend has investors snapping up shares today.
